Podcasts about calico labs

30 Years of Aging Biology: A Pioneer's Perspective (Cynthia Kenyon - VP Aging Biology, Calico Labs)Dr. Cynthia Kenyon reflects on the evolution of the longevity field over the 30 years since the publication of her groundbreaking paper, “A C. elegans mutant that lives twice as long as wild type,” a genetic analysis of one of the first single-gene mutations to extend lifespan in the worm. She recounts the initial excitement and skepticism around the idea of a pathway that regulates aging, and subsequent validation of this and related ideas in a wide range of model organisms. She also discusses her longstanding belief in the translational potential to improve human healthspan, and her experience as a co-founder of one of the first longevity biotech startups, Elixir Pharmaceuticals, in 1999. Based on her unique historical perspective—and with undiminished enthusiasm—she looks ahead to the unsolved mysteries that will propel the next generation of breakthroughs.Key ideas:Origins of looking at aging regulation in C. elegans in the 1990sage-1 and daf-2 as the first aging genesEarly resistance to the idea of studying aging at the molecular levelCloning of genes to reveal conserved longevity pathways (IIS/mTOR)Extending lifespan in invertebrates, and then miceThe connection between stress resistance to evolutionary theoryDr. Kenyon's initial belief in the translatability of aging scienceCo-founding Elixir Pharmaceuticals in 1999 to target agingCurrent optimism about interventions against agingNeed for public funding of large trials of natural compoundsExcitement about newest mechanisms like reprogrammingThe enduring promise of targeting core nutrient-sensing networksDevelopmental origins of aging rates and resilienceLinks: Email questions, comments, and feedback to podcast@bioagelabs.comTranslating Aging on Twitter: @bioagepodcastBioAge Labs Website bioagelabs.comBioAge Labs Twitter @bioagelabsBioAge Labs LinkedIn

We all know it, even if we try our best not to dwell on it: one day, we will age and eventually die. Or will we?Sara engages in a conversation with Sebastian Brunemeier to explore the potential reversal of aging and the prospect of avoiding death. Sebastian Brunemeier is a General Partner at Healthspan Capital, a venture fund focused on longevity biotech and regenerative medicine. He is also CEO of ImmuneAGE Bio, a drug discovery platform for immune system rejuvenation. He was previously co-founder and CIO at Cambrian Biopharma, one of the largest longbio companies, Founder and COO of Samsara Therapeutics, a clinical-stage autophagy drug discovery company in Oxford UK, and Principal at Apollo Health Ventures, the largest aging-focused venture fund with 200M under management. He was a Fulbright Scholar on telomere biology, holds a master's degree in molecular neuroscience and biotech business management from the University of Amsterdam, and was in the PhD program on the biochemistry of aging at Oxford as a Clarendon scholar before dropping out to launch Cambrian. He is an advisor to several companies including VitaDAO, the longevity DAO00:00 Introduction01:35 Understanding the connection between aging and mortality07:26 The pursuit of biological immortality11:24 Strategies for prolonging life15:45 Promising areas of research in the field of longevity24:10 Exploring autophagy during fasting26:03 Sebastian's personal longevity regimen28:05 Overrated and underrated aspects of longevity research32:29 Gender disparities in longevity studies35:17 Contributing to longevity research efforts37:28 Web3 and its intersection with biotech42:00 Should we truly extend human lifespan? Examining the downsides and longevity dividends48:39 The Vitalism movement54:00 Societal transformations in a world without aging01:02:03 The impact of an extended lifespan on birth rates

Over time, drug development has become more and more challenging.Success rates of clinical trials hover in the single digits, and the cost of developing a new treatment is greater than $2.5B.So, what can we do to make drug discovery faster, less expensive and more successful? How might advancements in machine learning and the availability of biomedical data revolutionize the drug design process?Daphne Koller is the CEO of Insitro, a company that is rethinking drug discovery using machine learning. She spent 18 years as a professor in the computer science department at Stanford before leaving to build the education platform Coursera. In 2016, Daphne returned to her passion for improving human health with machine learning, first as Chief Computing Officer at Calico Labs and then as the Founder of Insitro.On this episode of HLTH Matters, Daphne joins host Dr. Gautam Gulati to explain how her experience with her father's autoimmune condition informs her work and why we need to rethink the fundamental categorization of disease. Daphne describes how releasing machines from our preconceptions of what's important uncovers new science around the drivers of disease and serves as a critical starting point for developing new interventions. Listen in for Daphne's insight on leveraging machine learning to improve clinical trials and learn why data collection should be part of the fabric of every biopharma company.Topics CoveredDaphne's background in machine learning, biology and medical dataHow Daphne's experience with her father's autoimmune disease informs her work at InsitroWhy we need to rethink the fundamental categorization of what disease isDaphne's insight on the history of machine learning and the danger in overhyping what the technology can doThe pros and cons of using end-to-end learning to make predictionsHow releasing machines from preconceptions of what's important helps uncover new scienceWhy understanding the drivers of disease is a critical starting point for developing new interventionsWhy data collection should be part of the fabric of every biopharma companyHow Daphne's work in machine learning can be used to improve clinical trialsWhy now is the right time for a company like InsitroHow Daphne thinks about privacy and issues of informed consent Connect with Daphne KollerInsitro Connect with Dr. Gautam GulatiHLTHDr. G. on LinkedInDr. G. on Twitter ResourcesCourseraArt Levinson at CalicoDr. Hal Barron at GSKAducanumabChasing My Cure: A Doctor's Race to Turn Hope into Action by David FajgenbaumInsitro's Partnership with GileadUK Biobank Introductory Quote[5:34] “What I really wanted to build was a company that rethought drug discovery and development from the ground up, using machine learning as a foundational tool.”

Le PDG d'Amazon, Jeff Bezos, vient d'investir 3 milliards de dollars dans une start-up américaine dont le but est rien moins que de trouver la clé du rajeunissement humain. Il n'est d'ailleurs pas le seul à s'intéresser à cette entreprise.Une start-up californienneJeff Bezos a donc rejoint les rangs des gros investisseurs qui ont souhaité aider de leurs deniers une toute nouvelle entreprise. En effet, elle a vu le jour en janvier dernier.Son nom est Altos Labs. La société a élu domicile dans la Silicon Valley, en Californie. La société est également présente au Royaume-Uni et pourrait s'implanter ailleurs dans l'avenir.Altos Labs a sollicité le concours de scientifiques prestigieux, qu'elle attire en leur promettant des salaires fabuleux.Prolonger la vie humaineL'objectif d'Altos Labs est la reprogrammation cellulaire. De quoi s'agit-il ? C'est une méthode révolutionnaire, qui vise rien de moins que le rajeunissement humain. Elle consiste en quelque sorte à transformer des cellules différenciées, qui constituent divers organes du corps, en cellules pluripotentes.De telles cellules existent déjà : ce sont des cellules souches, capables de se différencier en n'importe quel type de cellule.Ces recherches sont considérées comme une avancée très prometteuse en matière de médecine régénérative, dont le but est de restaurer les organes et les tissus malades. Mais cette reprogrammation cellulaire pourrait avoir un but encore plus ambitieux : la prolongation de la vie humaine.Appliqué à l'organisme tout entier, ce rajeunissement des cellules pourrait contribuer à l'augmentation de l'espérance de vie.Dans un domaine aussi novateur, les investisseurs d'Altos n'attendent pas des résultats trop rapides. Mais ils espèrent que les travaux qui y seront menés ouvriront de nouvelles perspectives à la médecine.Ces techniques ont déjà été utilisées, avec un certain succès, pour prolonger la vie de souris de laboratoire. Ces expériences sur les animaux pourraient être poursuivies. Puis, dans un second temps, il sera peut-être possible d'envisager la reprogrammation de cellules humaines.Altos n'est pas la première entreprise à s'être intéressée à la reprogrammation cellulaire. Une autre société, Calico Labs, s'y consacre déjà depuis 2013, mais sans grands résultats pour l'instant. Voir Acast.com/privacy pour les informations sur la vie privée et l'opt-out.

This week Matthew is joined by Cynthia Kenyon, Vice President of Aging Research at Calico Labs, to discuss all things aging, worms, and proving others wrong. Tune in as Cynthia walks us through her discovery of controlled aging mechanisms and shows how important it is to be unapologetically curious, even in the face of judgement.

In this episode, Jacob Schreiber interviews David Kelley about machine learning models that can yield insight into the consequences of mutations on the genome. They begin their discussion by talking about Calico Labs, and then delve into a series of papers that David has written about using models, named Basset and Basenji, that connect genome sequence to functional activity and so can be used to quantify the effect of any mutation. Links: Calico Labs Basset: Learning the regulatory code of the accessible genome with deep convolutional neural networks (David R. Kelley, Jasper Snoek, and John Rinn) Sequential regulatory activity prediction across chromosomes with convolutional neural networks (David R. Kelley, Yakir A. Reshef, Maxwell Bileschi, David Belanger, Cory Y. McLean, and Jaspar Snoek) Cross-species regulatory sequence activity prediction (David R. Kelley) Basenji GitHub Repo

Daphne Koller, Co-Founder of Coursera & Former Chief Computing Officer at Calico Labs, and Elizabeth Dwoskin, Silicon Valley Correspondent, Washington Post. From the CB Insights A-ha! Conference, December 13, 2017. For more information visit events.cbinsights.com

Phil and Stephen discuss three animals who might well show us how to live longer and healthier lives. Secrets of these 200-year-old whales who avoid cancer Why the bowhead whale lives 200 years and rarely gets cancer. Naked mole rats defy the biological law of aging In the world of animal models, naked mole rats are the supermodels. They rarely get cancer, are resistant to some types of pain, and can survive up to 18 minutes without oxygen. But perhaps their greatest feat, a new paper suggests, is that they don't age.” Google’s Calico Labs announces discovery of a “non-aging mammal.” In the first significant announcement since it was formed in 2013, Calico Labs researchers Rochelle Buffenstein, Megan Smith, and J. Graham Ruby announce that the naked mole rat is a “non-aging mammal.” Axolotl genome sequenced, revealing regeneration genes If you lose an arm or a leg, there's a whole range of advanced prosthetics to give you some functionality back. But we might not need any artificial help in the long run if research into limb regeneration bears fruit. Scientists have now sequenced the genome of the Mexican axolotl, and have identified a few key genes hidden amongst its extremely complex genetic blueprint. WT 397-709 Eternity Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 3.0 License creativecommons.org/licenses/by/3.0/

In this episode, I speak with Arthur Gretton, Wittawat Jitkrittum, Zoltan Szabo and Kenji Fukumizu, who, alongside Wenkai Xu authored the 2017 NIPS Best Paper Award winner “A Linear-Time Kernel Goodness-of-Fit Test.” In our discussion, we cover what exactly a “goodness of fit” test is, and how it can be used to determine how well a statistical model applies to a given real-world scenario. The group and I the discuss this particular test, the applications of this work, as well as how this work fits in with other research the group has recently published. Enjoy! In our discussion, we cover what exactly a “goodness of fit” test is, and how it can be used to determine how well a statistical model applies to a given real-world scenario. The group and I the discuss this particular test, the applications of this work, as well as how this work fits in with other research the group has recently published. Enjoy! This is your last chance to register for the RE•WORK Deep Learning and AI Assistant Summits in San Francisco, which are this Thursday and Friday, January 25th and 26th. These events feature leading researchers and technologists like the ones you heard in our Deep Learning Summit series last week. The San Francisco will event is headlined by Ian Goodfellow of Google Brain, Daphne Koller of Calico Labs, and more! Definitely check it out and use the code TWIMLAI for 20% off of registration. The notes for this show can be found at twimlai.com/talk/100.

In this episode I speak with Tuomas Sandholm, Carnegie Mellon University Professor and Founder and CEO of startups Optimized Markets and Strategic Machine. Tuomas, along with his PhD student Noam Brown, won a 2017 NIPS Best Paper award for their paper “Safe and Nested Subgame Solving for Imperfect-Information Games.” Tuomas and I dig into the significance of the paper, including a breakdown of perfect vs imperfect information games, the role of abstractions in game solving, and how the concept of safety applies to gameplay. We discuss how all these elements and techniques are applied to poker, and how the algorithm described in this paper was used by Noam and Tuomas to create Libratus, the first AI to beat top human pros in No Limit Texas Hold’em, a particularly difficult game to beat due to its large state space. This was a fascinating interview that I'm really excited to share with you all. Enjoy! This is your last chance to register for the RE•WORK Deep Learning and AI Assistant Summits in San Francisco, which are this Thursday and Friday, January 25th and 26th. These events feature leading researchers and technologists like the ones you heard in our Deep Learning Summit series last week. The San Francisco will event is headlined by Ian Goodfellow of Google Brain, Daphne Koller of Calico Labs, and more! Definitely check it out and use the code TWIMLAI for 20% off of registration. The notes for this show can be found at twimlai.com/talk/99

In today’s show, I sit down with Eric Humphrey, Research Scientist in the music understanding group at Spotify. Eric was at the Deep Learning Summit to give a talk on Advances in Deep Architectures and Methods for Separating Vocals in Recorded Music. We discuss his talk, including how Spotify's large music catalog enables such an experiment to even take place, the methods they use to train algorithms to isolate and remove vocals from music, and how architectures like U-Net and Pix2Pix come into play when building his algorithms. We also hit on the idea of “creative AI,” Spotify’s attempt at understanding music content at scale, optical music recognition, and more. This show is part of a series of shows recorded at the RE•WORK Deep Learning Summit in Montreal back in October. This was a great event and, in fact, their next event, the Deep Learning Summit San Francisco is right around the corner on January 25th and 26th, and will feature more leading researchers and technologists like the ones you’ll hear here on the show this week, including Ian Goodfellow of Google Brain, Daphne Koller of Calico Labs, and more! Definitely check it out and use the code TWIMLAI for 20% off of registration. The notes for this show can be found at twimlai.com/talk/98

In this show I speak with Greg Diamos, senior computer systems researcher at Baidu. Greg joined me before his talk at the Deep Learning Summit, where he spoke on “The Next Generation of AI Chips.” Greg’s talk focused on some work his team was involved in that accelerates deep learning training by using mixed 16-bit and 32-bit floating point arithmetic. We cover a ton of interesting ground in this conversation, and if you’re interested in systems level thinking around scaling and accelerating deep learning, you’re really going to like this one. And of course, if you like this one, you’re also going to like TWiML Talk #14 with Greg’s former colleague, Shubho Sengupta, which covers a bunch of related topics. This show is part of a series of shows recorded at the RE•WORK Deep Learning Summit in Montreal back in October. This was a great event and, in fact, their next event, the Deep Learning Summit San Francisco is right around the corner on January 25th and 26th, and will feature more leading researchers and technologists like the ones you’ll hear here on the show this week, including Ian Goodfellow of Google Brain, Daphne Koller of Calico Labs, and more! Definitely check it out and use the code TWIMLAI for 20% off of registration.